Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
12.82
+0.18 (1.42%)
At close: Oct 15, 2026, 4:00 PM EDT
12.85
+0.03 (0.23%)
After-hours: Oct 15, 2026, 7:59 PM EDT
Novavax Market Cap
Novavax has a market cap or net worth of $2.11 billion as of October 15, 2026. It is the 6,429th most valuable company in the world and the 1,726th biggest in the United States. Its market cap has increased by 46.45% in one year.
Market Cap
2.11B
Enterprise Value
1.69B
1-Year Change
46.45%
Global Rank
Country Rank
#1,726 United States
Category
ChartMarket Cap Chart
Since December 1, 1998, Novavax's market cap has increased from $25.70M to $2.11B, an increase of 8,128.03%. That is a compound annual growth rate of 17.13%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 15, 2026 | 2.11B | 93.65% |
| Dec 31, 2025 | 1.09B | -15.21% |
| Dec 31, 2024 | 1.29B | 125.87% |
| Dec 29, 2023 | 570.20M | -29.34% |
| Dec 30, 2022 | 807.00M | -92.54% |
| Dec 31, 2021 | 10.82B | 52.38% |
| Dec 31, 2020 | 7.10B | 6,609.55% |
| Dec 31, 2019 | 105.80M | -84.98% |
| Dec 31, 2018 | 704.40M | 81.13% |
| Dec 29, 2017 | 388.90M | 13.78% |
| Dec 30, 2016 | 341.80M | -84.90% |
| Dec 31, 2015 | 2.26B | 60.10% |
| Dec 31, 2014 | 1.41B | 32.47% |
| Dec 31, 2013 | 1.07B | 281.83% |
| Dec 31, 2012 | 279.60M | 92.96% |
| Dec 30, 2011 | 144.90M | -46.33% |
| Dec 31, 2010 | 270.00M | 8.56% |
| Dec 31, 2009 | 248.70M | 90.28% |
| Dec 31, 2008 | 130.70M | -36.71% |
| Dec 31, 2007 | 206.50M | -18.35% |
| Dec 29, 2006 | 252.90M | 33.74% |
| Dec 30, 2005 | 189.10M | 46.70% |
| Dec 31, 2004 | 128.90M | -28.82% |
| Dec 31, 2003 | 181.10M | 182.53% |
| Dec 31, 2002 | 64.10M | -80.46% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Celldex Therapeutics | 2.20B |
| Aurinia Pharmaceuticals | 2.19B |
| Disc Medicine | 2.18B |
| Harmony Biosciences Holdings | 2.15B |
| Pharvaris | 2.12B |
| Vericel | 2.07B |
| Viridian Therapeutics | 2.06B |
| Recursion Pharmaceuticals | 2.06B |